AZN has been the subject of a number of other reports. Barclays reissued an overweight rating and set a £115 ($146.57) price objective on shares of AstraZeneca in a report on Wednesday, April 13th. UBS Group set a £105 ($133.83) price objective on AstraZeneca in a report on Monday, March 7th. Credit Suisse Group set a £110 ($140.20) price target on AstraZeneca in a report on Friday, April 8th. JPMorgan Chase & Co. set a £120 ($152.94) price target on AstraZeneca in a report on Wednesday. Finally, Deutsche Bank Rese… set a £115 ($146.57) price target on AstraZeneca in a report on Wednesday, April 6th. Two research analysts have rated the stock with a sell rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of £104.36 ($133.01).
Shares of LON AZN opened at £106.88 ($136.22) on Friday. The stock has a market cap of £165.61 billion and a PE ratio of 1,696.51. The business has a fifty day moving average of GBX 9,833.12 and a two-hundred day moving average of GBX 9,063.05. AstraZeneca has a 52-week low of GBX 7,502 ($95.62) and a 52-week high of £110 ($140.20). The company has a debt-to-equity ratio of 82.58, a quick ratio of 0.67 and a current ratio of 1.16.
About AstraZeneca (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.